This article describes the chemical modification of polyethylene terephthalate (PET) with a variety of compounds containing reactive glycidyl group(s). Four different modifiers, namely, diglycidyl ether of bisphenol‐A (DGEBA), N,N′‐bis[3(carbo‐2′,3′‐epoxypropoxy) phenyl] pyromellitimide (BGPM), triglycidyl glycerol (TGG), and triglycidyl isocyanurate (TGIC) were compared for their reactivity toward PET in the melt phase. It was found that the presence of tertiary nitrogen in the structure of the epoxide modifiers plays the role of in‐built catalyst for their reaction with the end groups of PET. TGIC as a modifier was selected for the detailed investigation of the simultaneously occurring degradation and chain extension/branching reactions in a batch‐melt mixer. The reactions were followed by torque changes, analyzing the products for residual carboxyl content, and by determining insoluble content. It is shown that the rate of the reactive modification of PET melt by TGIC depends upon stoichiometry, temperature, rate of shear, and the chemical composition and the molecular weight (MW) of the PET resin. In general, the results indicate an increase in melt viscosity and insoluble content, whereas an overall decrease in carboxyl content occurs, as defined by the choice of mixing conditions and stoichiometry. Analysis of the batch kinetic data can be useful to define the process requirements for carrying out the reactive modification in continuous extrusion equipment. © 2002 Wiley Periodicals, Inc. J Appl Polym Sci 87: 643–652, 2003

Activation of the immune system and increased synthesis of extracellular matrix proteins by fibroblasts are hallmarks in the pathogenesis of systemic sclerosis (SSc). The mechanisms that initiate the accumulation of inflammatory cells are still unknown. Chemokines are a family of small molecules that are divided into subfamilies according to the position of NH2-terminal cysteine motif. A new nomenclature for chemokines recently has been introduced in an attempt to overcome the confusion resulting from a number of different names for the same chemokines. Recent data indicate that chemokines, and in particular MCP-1 (CCL2), might be involved in the pathogenesis of SSc at different levels. MCP-1 is highly upregulated in skin specimens from SSc patients compared with those from healthy controls. Dermal fibroblasts release MCP-1, which is able to induce and perpetuate the migration of inflammatory cells into the skin. Interestingly, data from animal models, as well as from in vitro studies, indicate that MCP-1 might also be involved in the increased synthesis of extracellular matrix proteins, by either direct or indirect mechanisms. In conclusion, chemokines represent interesting candidates for target-directed therapies for SSc. This concept has to be confirmed by further studies using animal models for SSc and other fibrotic diseases.